Yahoo
NasdaqGS - Delayed Quote USD

NovoCure Limited (NVCR)

16.62 +1.41 (+9.27%)
At close: May 1 at 4:00:00 PM EDT
16.59 -0.03 (-0.18%)
After hours: May 1 at 7:50:44 PM EDT
Trade NVCR on Coinbase
NVCR Q1 2026 earnings call
Replay the call for the latest insights.
Read transcript
Chart Range Bar
Loading chart for NVCR
  • Previous Close 15.21
  • Open 15.43
  • Bid 11.96 x 100
  • Ask 20.60 x 100
  • Day's Range 15.35 - 16.70
  • 52 Week Range 9.82 - 20.06
  • Volume 3,533,864
  • Avg. Volume 2,028,456
  • Market Cap (intraday) 1.925B
  • Beta (5Y Monthly) 0.82
  • PE Ratio (TTM) --
  • EPS (TTM) -1.53
  • Earnings Date (est.) Jul 23, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 25.21

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

www.novocure.com

1,605

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Performance Overview: NVCR

Trailing total returns as of 5/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NVCR
28.54%
S&P 500 (^GSPC)
5.62%

1-Year Return

NVCR
7.41%
S&P 500 (^GSPC)
29.01%

3-Year Return

NVCR
75.16%
S&P 500 (^GSPC)
73.47%

5-Year Return

NVCR
91.86%
S&P 500 (^GSPC)
72.92%

Earnings Trends: NVCR

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 174.06M
Earnings -71.14M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-50M
0
50M
100M
150M

Analyst Insights: NVCR

View More

Analyst Price Targets

13.50
25.21 Average
16.62 Current
48.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/1/2026
Analyst Evercore ISI Group
Rating Action Maintains
Rating Outperform
Price Action Raises
Price Target 16 -> 20

Statistics: NVCR

View More

Valuation Measures

Annual
As of 5/1/2026
  • Market Cap

    1.92B

  • Enterprise Value

    1.73B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.77

  • Price/Book (mrq)

    5.81

  • Enterprise Value/Revenue

    2.56

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -25.66%

  • Return on Assets (ttm)

    -10.91%

  • Return on Equity (ttm)

    -49.97%

  • Revenue (ttm)

    674.41M

  • Net Income Avi to Common (ttm)

    -173.05M

  • Diluted EPS (ttm)

    -1.53

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    432M

  • Total Debt/Equity (mrq)

    71.04%

  • Levered Free Cash Flow (ttm)

    --

Compare To: NVCR

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: NVCR

Fair Value

16.62 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: